Skip to main content
. Author manuscript; available in PMC: 2020 Aug 22.
Published in final edited form as: Cell. 2019 Aug 8;178(5):1231–1244.e11. doi: 10.1016/j.cell.2019.07.033

Figure 2. GDF15 is required for survival of acute inflammatory states.

Figure 2.

(A) Survival after intraperitoneal injection of LPS following pre-treatment with either isotype or α-GDF15 antibody. (n=10 per group)

(B) Survival after retro-orbital injection of Poly(I:C) following pre-treatment with either isotype or α-GDF15 antibody. (n>9 per group)

(C) Images of cFos staining in the area postrema (AP, highlighted in pink) four hours after intraperitoneal injection of LPS following pre-treatment with either isotype or α-GDF15 antibody.

(D) Quantification of cFos staining in the area postrema four hours after intraperitoneal injection of LPS following pre-treatment with either isotype or α-GDF15 antibody.

(E) Plasma TNFα levels in mice 0, 2, 6, and 21 hours after intraperitoneal injection of LPS following pre-treatment with either isotype or α-GDF15 antibody. (n>4 per group)

(F) Plasma IL-12 levels in mice 0, 2, 6, and 21 hours after intraperitoneal injection of LPS following pre-treatment with either isotype or α-GDF15 antibody. (n>4 per group)

(G) Plasma IFNα levels in mice 0, 3, and 6 hours after retro-orbital injection of Poly(I:C) following pre-treatment with either isotype or α-GDF15 antibody. (n>5 per group)